J William Harbour

List of Publications by Year
in descending order

221 papers	16,975 citations	17440 63 h-index	16183 124 g-index
237 all docs	237 docs citations	237 times ranked	14057 citing authors

#	Article	IF	Citations
1	Multiple Genetically Distinct Uveal Melanomas Arise in the Same Eye of Two Patients with Melanosis Oculi. American Journal of Ophthalmology, 2022, 234, 1-5.	3.3	0
2	The AMPâ€dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma. Pigment Cell and Melanoma Research, 2022, 35, 78-87.	3.3	12
3	Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia. International Journal of Biological Macromolecules, 2022, 195, 93-101.	7.5	8
4	Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma. Oncogene, 2022, , .	5.9	6
5	HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Therapy, 2022, 29, 1840-1846.	4.6	3
6	Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma. Molecular Cancer Research, 2022, 20, 1260-1271.	3.4	9
7	Hematologic Complications Associated With Intra-arterial Chemotherapy for Retinoblastoma Treatment: A Single Institution Experience. Journal of Pediatric Hematology/Oncology, 2022, 44, 181-185.	0.6	3
8	Choroidal Nevus and Melanocytoma. , 2022, , 7795-7805.		0
9	Intraocular Lymphoma. , 2022, , 7783-7793.		0
10	Abstract 1672: Effect of BCOR loss in Xenopus laevis and tropicalis: Insights for retinal development and retinoblastoma. Cancer Research, 2022, 82, 1672-1672.	0.9	0
11	RETINOCYTOMA WITH VITREOUS SEEDING: NEW INSIGHTS FROM ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY AND HIGH-RESOLUTION POSTERIOR SEGMENT ULTRASONOGRAPHY. Retinal Cases and Brief Reports, 2021, 15, 68-70.	0.6	2
12	Chimerism involving a <scp>RB1</scp> pathogenic variant in monochorionic dizygotic twins with twinâ€“twin transfusion syndrome. American Journal of Medical Genetics, Part A, 2021, 185, 208-212.	1.2	2
13	Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma. Molecular Cancer Research, 2021, 19, 215-222.	3.4	21
14	BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene, 2021, 40, 618-632.	5.9	28
15	Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. Molecular Cancer Research, 2021, 19, 1099-1112.	3.4	1
16	Therapeutic Escape in GÎ±q-mutant Uveal Melanoma: It's a FAK. Clinical Cancer Research, 2021, 27, 2967-2969.	7.0	4
17	PieParty: visualizing cells from scRNA-seq data as pie charts. Life Science Alliance, 2021, 4, e202000986.	2.8	2
18	Multimodal Imaging in the Diagnosis of Exophytic Juxtapapillary Retinal Capillary Hemangioblastoma. American Journal of Ophthalmology, 2021, 225, 128-136.	3.3	6

#	Article	IF	Citations
19	Uphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data. BMC Genomics, 2021, 22, 419.	2.8	17
20	Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry. Brachytherapy, 2021, 20, 1289-1295.	0.5	2
21	Abstract 2764: Mechanisms of genomic-microenvironmental interactions in uveal melanoma. , 2021, , .		0
22	Iris Mass in a 14-Month-Old Boy. JAMA Ophthalmology, 2021, 139, 802.	2.5	0
23	Secondary Glaucoma Associated with Intraocular Metastatic Cutaneous Melanoma. Ophthalmology Glaucoma, 2021, 5, 119-119.	1.9	0
24	Analytical Validation and Performance of a 7-Gene Next-Generation Sequencing Panel in Uveal Melanoma. Ocular Oncology and Pathology, 2021, 7, 428-436.	1.0	1
25	Multiregional genetic evolution of metastatic uveal melanoma. Npj Genomic Medicine, 2021, 6, 70.	3.8	9
26	Intraocular Lymphoma. , 2021, , 1-11.		0
27	Structural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma. Genes, 2021, 12, 1625.	2.4	5
28	Waking Up With Cloudy Vision. JAMA Ophthalmology, 2021, , .	2.5	0
29	Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell and Melanoma Research, 2020, 33, 507-514.	3.3	17
30	Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discovery, 2020, 10, 1103-1120.	9.4	144
31	A novel cardiomyogenic role for Isl1 ⁺ neural crest cells in the inflow tract. Science Advances, 2020, 6, .	10.3	10
32	Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma. Cancers, 2020, 12, 3208.	3.7	2
33	Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncology, 2020, 6, 685.	7.1	192
34	Single-cell analysis of olfactory neurogenesis and differentiation in adult humans. Nature Neuroscience, 2020, 23, 323-326.	14.8	165
35	Influence of tumor shape and location in eye plaque brachytherapy dosimetry. Brachytherapy, 2020, 19, 249-254.	0.5	4
36	Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nature Communications, 2020, 11, 496.	12.8	268

#	Article	IF	Citations
37	Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. American Journal of Ophthalmology Case Reports, 2020, 18, 100691.	0.7	9
38	BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas. Clinical Cancer Research, 2019, 25, 5663-5673.	7.0	41
39	Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma. Journal of Ophthalmic Inflammation and Infection, 2019, 9, 11.	2.2	3
40	BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Science Advances, 2019, 5, eaax1738.	10.3	57
41	Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations. JAMA Ophthalmology, 2019, 137, 1434.	2.5	6
42	Bilateral radiation therapy followed by methotrexateâ€based chemotherapy for primary vitreoretinal lymphoma. American Journal of Hematology, 2019, 94, 455-460.	4.1	22
43	Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a. Clinical Cancer Research, 2019, 25, 5156-5166.	7.0	16
44	HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical Cancer Research, 2019, 25, 5686-5701.	7.0	75
45	Genomic evolution of uveal melanoma arising in ocular melanocytosis. Journal of Physical Education and Sports Management, 2019, 5, a004051.	1.2	12
46	Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. Brachytherapy, 2019, 18, 404-410.	0.5	7
47	Persistent fetal vasculature presenting with axial elongation and platyphakia. Journal of AAPOS, 2019, 23, 51-53.	0.3	0
48	Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker. American Journal of Ophthalmology, 2019, 197, 168-179.	3.3	28
49	CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. Leukemia and Lymphoma, 2019, 60, 1308-1311.	1.3	5
50	ChIPprimersDB: a public repository of verified qPCR primers for chromatin immunoprecipitation (ChIP). Nucleic Acids Research, 2019, 47, D46-D49.	14.5	9
51	Follow the nevus: the cost-utility of monitoring for growth of choroidal nevi. International Journal of Ophthalmology, 2019, 12, 1456-1464.	1.1	1
52	Intraocular Dissemination of Uveal Melanoma Cells Following Radiotherapy: Evolving Management Over the Past Decade. Ophthalmic Surgery Lasers and Imaging Retina, 2019, 50, 573-579.	0.7	3
53	Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo. Leukemia, 2018, 32, 1834-1837.	7.2	20
54	Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Research, 2018, 78, 1200-1213.	0.9	24

#	Article	IF	Citations
55	Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nature Communications, 2018, 9, 116.	12.8	144
56	Retinoblastoma With Endophytic and Exophytic Features. JAMA Ophthalmology, 2018, 136, e175064.	2.5	1
57	Anterior Chamber Chemotherapy in Retinoblastomaâ€"Necessary But Not Sufficient for Aqueous Seeding Controlâ€"Reply. JAMA Ophthalmology, 2018, 136, 597.	2.5	1
58	Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood, 2018, 131, 328-341.	1.4	133
59	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164
60	Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nature Communications, 2018, 9, 5315.	12.8	78
61	Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma. American Journal of Ophthalmology, 2018, 195, 154-160.	3.3	44
62	Congenital Hypertrophy of the Retinal Pigment Epithelium Presenting With Secondary Choroidal Neovascularization. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 276-277.	0.7	2
63	Diagnosis of Bilateral Retinocytoma in an Adolescent Patient Using Multimodal Imaging and Genetic Testing. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 812-814.	0.7	0
64	Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanomaâ€"Reply. JAMA Ophthalmology, 2017, 135, 175.	2.5	4
65	ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. Science Advances, 2017, 3, e1601602.	10.3	35
66	PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmology, 2017, 135, 541.	2.5	87
67	Incorporating Clinical, Histological, and Genetic Parameters for Choroidal Melanoma Prognosticationâ€"Reply. JAMA Ophthalmology, 2017, 135, 819.	2.5	1
68	Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma. Ophthalmology, 2017, 124, 1532-1539.	5.2	24
69	Liquid Biopsy in Retinoblastoma. JAMA Ophthalmology, 2017, 135, 1231.	2.5	2
70	Fluorescein angiography findings in diffuse retinoblastoma: two case reports with clinicopathologic correlation. Journal of AAPOS, 2017, 21, 337-339.e2.	0.3	7
71	Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing. JAMA Ophthalmology, 2017, 135, 1434.	2.5	40
72	Intracameral Topotecan Hydrochloride for Anterior Chamber Seeding of Retinoblastoma. JAMA Ophthalmology, 2017, 135, 1453.	2.5	11

#	Article	IF	Citations
73	Multimodal Imaging of Astrocytic Hamartomas Associated With Tuberous Sclerosis. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 756-758.	0.7	5
74	Letter to the Editor: Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas. , 2017, 58, 5444.		0
75	An international survey of classification and treatment choices for group D retinoblastoma. International Journal of Ophthalmology, 2017, 10, 961-967.	1.1	30
76	Preclinical Acute Ocular Safety Study of Combined Intravitreal Carboplatin and Etoposide Phosphate for Retinoblastoma. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 151-159.	0.7	8
77	Retinoblastoma: Clinical and Molecular Perspectives. , 2017, , 355-361.		0
78	Uveal Melanoma. , 2017, , 4767-4772.		0
79	Abstract 4348: Methylation analysis of uveal melanoma reveals definitive patterns in tumors harboring BAP1 mutations. , 2017, , .		0
80	Abstract 794: Potential role of DLL4 in uveal melanoma vascular mimicry. , 2017, , .		0
81	Abstract 5369: Epigenetic, transciptomic and ubiquitomic changes associated with BAP1 loss in uveal melanoma. , 2017, , .		0
82	Abstract 1541: The tumor suppressor BAP1 promotes a developmental switch from pluripotency to differentiation. Cancer Research, 2017, 77, 1541-1541.	0.9	1
83	Abstract 3390: Clonal evolution in uveal melanoma. , 2017, , .		0
84	PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clinical Cancer Research, 2016, 22, 1234-1242.	7.0	205
85	Driver Mutations in Uveal Melanoma. JAMA Ophthalmology, 2016, 134, 728.	2.5	192
86	Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma. JAMA Ophthalmology, 2016, 134, 734.	2.5	101
87	An Iris Tumor. JAMA Ophthalmology, 2016, 134, 1063.	2.5	0
88	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
89	A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Research, 2016, 26, 481-486.	1.2	9
90	ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell, 2016, 29, 889-904.	16.8	128

#	Article	IF	Citations
91	Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget, 2016, 7, 59209-59219.	1.8	94
92	Skewed Expression of the Genes Encoding Epigenetic Modifiers in High-Risk Uveal Melanoma. Investigative Ophthalmology and Visual Science, 2015, 56, 1447-1458.	3.3	34
93	Serous Macular Detachment Following a Systemic Corticosteroid Injection. JAMA Ophthalmology, 2015, 133, 473.	2.5	1
94	Hydroxyapatite versus polyethylene orbital implants for patients undergoing enucleation for uveal melanoma. Canadian Journal of Ophthalmology, 2015, 50, 151-154.	0.7	9
95	Epigenetic reprogramming of melanoma cells by vitamin C treatment. Clinical Epigenetics, 2015, 7, 51.	4.1	74
96	Molecular Biology of Retinoblastoma. Essentials in Ophthalmology, 2015, , 1-13.	0.1	0
97	Abstract 4262: PRAME as a biomarker for a new molecular subclass of uveal melanoma. , 2015, , .		1
98	Gene Expression Profiling and Regression Rate of Irradiated Uveal Melanomas. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 333-337.	0.7	10
99	Spectral-Domain Optical Coherence Tomography of Presumed Solitary Circumscribed Retinal Astrocytic Proliferation Versus Astrocytic Hamartoma. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 586-588.	0.7	14
100	Retinoblastoma Tumorigenesis. , 2015, , 61-68.		0
101	Second Primary Tumors in Retinoblastoma. , 2015, , 37-41.		0
102	EMT-associated factors promote invasive properties of uveal melanoma cells. Molecular Vision, 2015, 21, 919-29.	1.1	26
103	Prognostic parameters in uveal melanoma and their association with BAP1 expression. British Journal of Ophthalmology, 2014, 98, 1738-1743.	3.9	111
104	Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 2021-2022.	1.9	4
105	Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene, 2014, 33, 4722-4723.	5.9	30
106	Recent developments in prognostic and predictive testing in uveal melanoma. Current Opinion in Ophthalmology, 2014, 25, 234-239.	2.9	141
107	Outcomes of Iodine-125 Plaque Brachytherapy for Uveal Melanoma With Intraoperative Ultrasonography and Supplemental Transpupillary Thermotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 801-805.	0.8	47
108	A Molecular Revolution in Uveal Melanoma. Ophthalmology, 2014, 121, 1281-1288.	5.2	76

#	Article	IF	Citations
109	GNAQ/11 Mutations in Uveal Melanoma: Is YAP the Key to Targeted Therapy?. Cancer Cell, 2014, 25, 714-715.	16.8	30
110	A Prognostic Test to Predict the Risk of Metastasis in Uveal Melanoma Based on a 15-Gene Expression Profile. Methods in Molecular Biology, 2014, 1102, 427-440.	0.9	105
111	Distinguishing Torpedo Maculopathy From Similar Lesions of the Posterior Segment. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 222-226.	0.7	19
112	Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nature Genetics, 2013, 45, 133-135.	21.4	447
113	Multimodal imaging of sarcoid choroidal granulomas. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 58.	2.2	41
114	BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer, 2013, 13, 371.	2.6	123
115	Gene Expression Profiling versus TNM Classification. Ophthalmology, 2013, 120, e52-e53.	5.2	3
116	Gene Expressing Profiling of Iris Melanomas. Ophthalmology, 2013, 120, 213-213.e3.	5.2	25
117	Patientâ€derived xenografts recapitulate molecular features of human uveal melanomas. Molecular Oncology, 2013, 7, 625-636.	4.6	46
118	Author reply. Ophthalmology, 2013, 120, e51.	5.2	5
119	Impaired Cholesterol Efflux in Senescent Macrophages Promotes Age-Related Macular Degeneration. Cell Metabolism, 2013, 17, 549-561.	16.2	212
120	Molecular testing prognostic of low risk in epithelioid uveal melanoma in a child. British Journal of Ophthalmology, 2013, 97, 323-326.	3.9	5
121	A Role for Jag2 in Promoting Uveal Melanoma Dissemination and Growth. , 2013, 54, 295.		26
122	Genomic, Prognostic, and Cell-Signaling Advances in Uveal Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 388-391.	3.8	16
123	Retinoblastoma protein prevents enteric nervous system defects and intestinal pseudo-obstruction. Journal of Clinical Investigation, 2013, 123, 5152-5164.	8.2	10
124	Genomic, Prognostic, and Cell-Signaling Advances in Uveal Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 388-391.	3.8	19
125	The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLOS Currents, 2013, 5, .	1.4	74
126	Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma. Clinical Cancer Research, 2012, 18, 408-416.	7.0	241

#	Article	IF	Citations
127	Notch Signaling Promotes Growth and Invasion in Uveal Melanoma. Clinical Cancer Research, 2012, 18, 654-665.	7.0	63
128	The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell and Melanoma Research, 2012, 25, 171-181.	3.3	150
129	I-125 Episcleral Plaque Brachytherapy for Uveal Melanoma: A 15-year Single Institution Experience. International Journal of Radiation Oncology Biology Physics, 2012, 84, S196.	0.8	0
130	Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma. Ophthalmology, 2012, 119, 1596-1603.	5.2	416
131	Uveal Melanoma: Molecular Pattern, Clinical Features, and Radiation Response. American Journal of Ophthalmology, 2012, 154, 227-232.e2.	3.3	39
132	High Throughput Mass Spectrometry-Based Mutation Profiling of Primary Uveal Melanoma. , 2012, 53, 6991.		43
133	Uveal Melanoma. , 2012, , 1-6.		0
134	Update in uveal melanoma. Clinical Advances in Hematology and Oncology, 2012, 10, 459-61.	0.3	3
135	ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity. Pigment Cell and Melanoma Research, 2011, 24, 430-437.	3.3	27
136	A new mutation with staggering effects. Pigment Cell and Melanoma Research, 2011, 24, 1081-1082.	3.3	0
137	DIAGNOSTIC TESTING AND TREATMENT CHOICES IN PRIMARY VITREORETINAL LYMPHOMA. Retina, 2011, 31, 435-440.	1.7	83
138	p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rbâ€“Hdm2 interaction and apoptosis. Oncogene, 2011, 30, 588-599.	5.9	42
139	Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium. Oncologist, 2011, 16, 1589-1599.	3.7	386
140	Abstract 1415: The Notch ligand Jag 2 promotes growth and invasion in uveal melanoma cells. Cancer Research, 2011, 71, 1415-1415.	0.9	1
141	Id2 deficiency promotes metastasis in a mouse model of ocular cancer. Clinical and Experimental Metastasis, 2010, 27, 91-96.	3.3	7
142	A Transformation in Ocular Oncology. JAMA Ophthalmology, 2010, 128, 367.	2.4	1
143	Loss of Id2 Potentiates the Tumorigenic Effect of Rb Inactivation in a Mouse Model of Retinoblastoma. Current Eye Research, 2010, 35, 435-439.	1.5	4
144	Review of 676 Second Primary Tumors in Patients With Retinoblastoma. JAMA Ophthalmology, 2010, 128, 865.	2.4	56

#	Article	IF	Citations
145	An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal Melanoma. Journal of Molecular Diagnostics, 2010, 12, 461-468.	2.8	290
146	Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas. Science, 2010, 330, 1410-1413.	12.6	1,242
147	Association between Gene Expression Profile, Proliferation and Metastasis in Uveal Melanoma. Current Eye Research, 2010, 35, 857-863.	1.5	36
148	Molecular basis of low-penetrance retinoblastoma. , 2010, , 377-382.		0
149	Uveal melanoma. , 2010, , 362-368.		0
150	Abstract 4141: Notch signaling: A new potential target in the treatment of uveal melanoma. , 2010, , .		1
151	Molecular Prognostic Testing and Individualized Patient Care in Uveal Melanoma. American Journal of Ophthalmology, 2009, 148, 823-829.e1.	3.3	61
152	Hepatic Metastasis From Uveal Melanoma. JAMA Ophthalmology, 2009, 127, 628.	2.4	35
153	Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma. American Journal of Roentgenology, 2008, 190, 99-104.	2.2	77
154	A Metastasis Modifier Locus on Human Chromosome 8p in Uveal Melanoma Identified by Integrative Genomic Analysis. Clinical Cancer Research, 2008, 14, 3737-3745.	7.0	95
155	Oncogenic Mutations inGNAQOccur Early in Uveal Melanoma. , 2008, 49, 5230.		329
156	Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncology, 2008, 4, 629-636.	2.4	100
157	Integrative Genomic Analysis of Aneuploidy in Uveal Melanoma. Clinical Cancer Research, 2008, 14, 115-122.	7.0	117
158	Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Research, 2008, 18, 184-190.	1.2	137
159	Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Research, 2008, 18, 191-200.	1.2	111
160	Correlation Study of Benign Cytomorphology and Final Clinical Diagnosis. Acta Cytologica, 2008, 52, 196-200.	1.3	9
161	Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma. JAMA Ophthalmology, 2008, 126, 65.	2.4	39
162	Current management of uveal melanoma. Expert Review of Ophthalmology, 2007, 2, 939-946.	0.6	27

#	Article	IF	Citations
163	Inhibiting Angiogenesis in Retinoblastoma. Ophthalmic Research, 2007, 39, 188-190.	1.9	16
164	Molecular prognostic testing in uveal melanoma. Expert Review of Ophthalmology, 2007, 2, 65-69.	0.6	0
165	Molecular Prognostic Testing in Uveal Melanoma. JAMA Ophthalmology, 2007, 125, 1122.	2.4	15
166	Loss of Heterozygosity of Chromosome 3 Detected with Single Nucleotide Polymorphisms Is Superior to Monosomy 3 for Predicting Metastasis in Uveal Melanoma. Clinical Cancer Research, 2007, 13, 2923-2927.	7.0	122
167	Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal Melanoma. Clinical Cancer Research, 2007, 13, 1466-1471.	7.0	145
168	Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye, 2007, 21, 1198-1201.	2.1	101
169	Cancer genetics. , 2007, , 31-33.		0
170	Prognostic Testing in Uveal Melanoma by Transcriptomic Profiling of Fine Needle Biopsy Specimens. Journal of Molecular Diagnostics, 2006, 8, 567-573.	2.8	73
171	Lipid Exudation Following Plaque Radiotherapy for Posterior Uveal Melanoma. American Journal of Ophthalmology, 2006, 141, 594-595.e1.	3.3	17
172	Eye Cancer: Unique Insights into Oncogenesis The Cogan Lecture. , 2006, 47, 1737.		35
173	Rb at the Interface Between Cell Cycle and Apoptotic Decisions. Current Molecular Medicine, 2006, 6, 713-718.	1.3	1
174	Molecular Pathobiology of Uveal Melanoma. International Ophthalmology Clinics, 2006, 46, 167-180.	0.7	36
175	Functional Gene Expression Analysis Uncovers Phenotypic Switch in Aggressive Uveal Melanomas. Cancer Research, 2006, 66, 4602-4609.	0.9	159
176	Rb at the Interface Between Cell Cycle and Apoptotic Decisions. Current Molecular Medicine, 2006, 6, 713-718.	1.3	40
177	Fine Needle Aspiration Biopsy with Adjunct Immunohistochemistry in Intraocular Tumor Management. Acta Cytologica, 2005, 49, 297-308.	1.3	65
178	Uveal Melanoma: Genetic Aspects. Ophthalmology Clinics of North America, 2005, 18, 85-97.	1.8	46
179	Functional Analysis of the p53 Pathway in Response to Ionizing Radiation in Uveal Melanoma. , 2005, 46, 1561.		47
180	MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. Journal of Cell Biology, 2005, 168, 35-40.	5.2	236

#	Article	IF	Citations
181	Loss of Rb-E2F Repression Results in Caspase-8-mediated Apoptosis through Inactivation of Focal Adhesion Kinase. Journal of Biological Chemistry, 2005, 280, 10484-10490.	3.4	17
182	NBS1 Expression as a Prognostic Marker in Uveal Melanoma. Clinical Cancer Research, 2005, 11, 1849-1853.	7.0	59
183	DDEF1 Is Located in an Amplified Region of Chromosome 8q and Is Overexpressed in Uveal Melanoma. Clinical Cancer Research, 2005, 11, 3609-3613.	7.0	135
184	Association Between Microarray Gene Expression Signature and Extravascular Matrix Patterns in Primary Uveal Melanomas. American Journal of Ophthalmology, 2005, 140, 748-749.	3.3	47
185	Cytologic Diagnosis of Intraocular Lymphoma in Vitreous Aspirates. Acta Cytologica, 2004, 48, 487-491.	1.3	51
186	Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death. Cancer Research, 2004, 64, 7205-7209.	0.9	661
187	Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi. British Journal of Ophthalmology, 2004, 88, 36-38.	3.9	29
188	Association between choroidal pigmentation and posterior uveal melanoma in a white population. British Journal of Ophthalmology, 2004, 88, 39-43.	3.9	41
189	For Whom the Bell Tolls: Susceptibility to Common Adult Cancers in Retinoblastoma Survivors. Journal of the National Cancer Institute, 2004, 96, 342-343.	6.3	26
190	Optical coherence tomography in the evaluation of retinal changes associated with suspicious choroidal melanocytic tumors. American Journal of Ophthalmology, 2004, 137, 90-95.	3.3	89
191	Photodynamic therapy for choroidal metastasis from carcinoid tumor. American Journal of Ophthalmology, 2004, 137, 1143-1145.	3.3	48
192	What is the best treatment for retinoblastoma?. American Journal of Ophthalmology, 2004, 138, 471-473.	3.3	11
193	Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma. American Journal of Ophthalmology, 2003, 136, 471-476.	3.3	42
194	Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology, 2003, 110, 2207-2214.	5.2	68
195	Molecular genetics of uveal melanoma. Current Eye Research, 2003, 27, 69-74.	1.5	18
196	Distinct Mechanisms for Regulating the Tumor Suppressor and Antiapoptotic Functions of Rb. Journal of Biological Chemistry, 2003, 278, 19358-19366.	3.4	54
197	Ocular Melanoma. Archives of Dermatology, 2003, 139, 1067.	1.4	85
198	Status of the NF1 Tumor Suppressor Locus in Uveal Melanoma. JAMA Ophthalmology, 2003, 121, 1311.	2.4	26

#	Article	IF	Citations
199	Rate of Resolution of Exudative Retinal Detachment After Plaque Radiotherapy for Uveal Melanoma. JAMA Ophthalmology, 2002, 120, 1463.	2.4	21
200	Transducible Peptide Therapy for Uveal Melanoma and Retinoblastoma. JAMA Ophthalmology, 2002, 120, 1341.	2.4	95
201	Photodynamic therapy for circumscribed choroidal hemangioma. Canadian Journal of Ophthalmology, 2002, 37, 314-317.	0.7	13
202	Altered expression of rb and p53 in uveal melanomas following plaque radiotherapy11The author has no proprietary interest in this study.. American Journal of Ophthalmology, 2002, 133, 242-248.	3.3	20
203	Risk Factors for Metastasis in Retinoblastoma. Survey of Ophthalmology, 2002, 47, 1-16.	4.0	187
204	The molecular biology of retinoblastoma. Ocular Immunology and Inflammation, 2001, 9, 1-8.	1.8	24
205	Molecular Basis of Low-Penetrance Retinoblastoma. JAMA Ophthalmology, 2001, 119, 1699.	2.4	102
206	Rb function in cell-cycle regulation and apoptosis. Nature Cell Biology, 2000, 2, E65-E67.	10.3	460
207	Chromatin remodeling and Rb activity. Current Opinion in Cell Biology, 2000, 12, 685-689.	5.4	130
208	The Rb/E2F pathway: expanding roles and emerging paradigms. Genes and Development, 2000, 14, 2393-2409.	5.9	984
209	Deregulation of the Rb and p53 Pathways in Uveal Melanoma. American Journal of Pathology, 2000, 157, 1795-1801.	3.8	110
210	Exit from G1 and S Phase of the Cell Cycle Is Regulated by Repressor Complexes Containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell, 2000, 101, 79-89.	28.9	615
211	Tumor Suppressor Genes in Ophthalmology. Survey of Ophthalmology, 1999, 44, 235-246.	4.0	9
212	Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1. Cell, 1999, 98, 859-869.	28.9	927
213	Langerhans Cell Histiocytosis Diagnosed by Fine Needle Biopsy. JAMA Ophthalmology, 1997, 115, 1212.	2.4	6
214	Metastatic Risk for Distinct Patterns of Postirradiation Local Recurrence of Posterior Uveal Melanoma. Ophthalmology, 1997, 104, 1785-1793.	5.2	82
215	Vitrectomy for Diabetic Macular Edema Associated With a Thickened and Taut Posterior Hyaloid Membrane. American Journal of Ophthalmology, 1996, 121, 405-413.	3.3	294
216	INTRAOPERATIVE ECHOGRAPHIC LOCALIZATION OF IODINE 125 EPISCLERAL RADIOACTIVE PLAQUES FOR POSTERIOR UVEAL MELANOMA. Retina, 1996, 16, 129-134.	1.7	100

#	Article	IF	Citations
217	Pars Plana Vitrectomy in the Management of Phakic and Pseudophakic Malignant Glaucoma. JAMA Ophthalmology, 1996, 114, 1073.	2.4	86
218	Initial Management and Follow-up of Melanocytic Iris Tumors. Ophthalmology, 1995, 102, 1987-1993.	5.2	59
219	Uveal Metastasis from Carcinoid Tumor. Ophthalmology, 1994, 101, 1084-1090.	5.2	82
220	Clivus Chordoma: A Report of 12 Recent Cases and Review of the Literature. Skull Base, 1991, 1, 200-206.	0.4	25
221	Abnormalities in Structure and Expression of the Human Retinoblastoma Gene in SCLC. Science, 1988, 241, 353-357.	12.6	870